EPISODE · Jun 22, 2026 · 1 MIN
Redefining Biomarker-Driven Care: Telisotuzumab Vedotin-tllv for Advanced Non-Squamous NSCLC
from TheBrief.Health · host TheBrief.Health
A newly approved c-Met–targeted antibody-drug conjugate offers a precision treatment option for previously treated advanced non-squamous NSCLC, expanding personalized therapy beyond genomic mutations alone.
What this episode covers
A newly approved c-Met–targeted antibody-drug conjugate offers a precision treatment option for previously treated advanced non-squamous NSCLC, expanding personalized therapy beyond genomic mutations alone.
NOW PLAYING
Redefining Biomarker-Driven Care: Telisotuzumab Vedotin-tllv for Advanced Non-Squamous NSCLC
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m